Raben N, Sherman J B, Adams E, Nakajima H, Argov Z, Plotz P
Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Muscle Nerve Suppl. 1995;3:S35-8. doi: 10.1002/mus.880181409.
Muscle phosphofructokinase (PFK-M) deficiency (glycogenosis type VII, Tarui's disease) is characterized by intolerance to vigorous exercise, often accompanied by myoglobinuria. The disease is inherited as an autosomal recessive trait. The clinical manifestations are similar to those in myophosphorylase deficiency (McArdle's disease), and the diagnosis required demonstration of the enzyme defect in muscle biopsy. In the Western hemisphere PFK deficiency appears to be prevalent among people of Ashkenazi Jewish descent. To define the molecular basis of this myopathy, we have studied 11 Ashkenazi and 2 non-Ashkenazi families with the disease. Ashkenazi patients share two common pathogenic mutations, a splicing defect and a nucleotide deletion, which account for approximately 95% of mutant alleles. The molecular diagnosis is now possible in this population by using simple PCR-based tests to screen for these mutations.
肌肉磷酸果糖激酶(PFK-M)缺乏症(糖原贮积病VII型,塔瑞氏病)的特征是不耐剧烈运动,常伴有肌红蛋白尿。该病以常染色体隐性特征遗传。其临床表现与肌磷酸化酶缺乏症(麦克尔氏病)相似,诊断需要在肌肉活检中证实酶缺陷。在西半球,PFK缺乏症在阿什肯纳兹犹太裔人群中似乎很普遍。为了确定这种肌病的分子基础,我们研究了11个患该病的阿什肯纳兹家族和2个非阿什肯纳兹家族。阿什肯纳兹患者共有两种常见的致病突变,一种剪接缺陷和一种核苷酸缺失,约占突变等位基因的95%。现在通过使用基于简单PCR的检测方法来筛查这些突变,在这一人群中进行分子诊断成为可能。